INTRODUCTION

24
Ibuprofen (IBP), a non-steroidal anti-inflammatory drug (NSAID) predominantly used to 25 treat pain and reduce inflammation and fever, is considered safe for oral ingestion within 
MATERIALS AND METHODS
88
Participants
89
Two independent groups of thirteen recreationally-active males (mean ± SD: age 31 ± 7 90 years, height 1.76 ± 0.08 m, body mass 75 ± 11 kg), and sixteen recreationally-active males 91 (mean ± SD: age 29 ± 9 years, height 1.79 ± 0.07 m, body mass 77 ± 8 kg, V O2peak 60.8 ± 7.8 92 ml·kg -1 ·min -1 ), volunteered for the first (A) and second (B) part of this study, respectively.
93
All participants provided written, informed consent to participate in this study, which was 94 approved by the Sport and Health Sciences Ethics Committee at the University of Exeter. the participants would achieve a power output equivalent to 50% of the difference between
157
GET and V O2peak (linear factor = 50%∆ peak aerobic power output/preferred cadence 2 ).
158
During this visit, the seat and handlebar positions were adjusted for comfort and replicated For part A and B, neuromuscular function was assessed pre-, during-and post-trial (< 10 s).
174
Single peripheral nerve stimulation pulses were manually triggered at rest to determine pre- protocol was determined as the mean value over a 1-s period which approximated the plateau 244 level of the highest torque (i.e. 500 ms before and after the peak torque). The pTw was 245 calculated as the peak torque achieved following the single pulse delivered 1-s post-MVC.
246
The twitch torque superimposed onto the peak force production of the MVC (sTw) was Voluntary activation (VA, %) was calculated using the interpolated twitch method from during the first contraction to 40 ± 15% MVC during the last 12 contractions (P<0.01, Table   303 1, figure 2a ). During the IBP trial torque declined from a peak of 99 ± 3% to 41 ± 16% MVC. and from 88 ± 7 to 60 ± 18%, EMG declined from 99 ± 4 to 59 ± 17% and 100 ± 2 to 64 ± 318 20% (from first 6 to last 6 contractions) and M-wave amplitude declined from 100 ± 1 to 96 ±
319
14% and 100 ± 1 to 95 ± 12% in the PL and IBP conditions, respectively (P<0.05), with no 320 differences between PL and IPB for any of these variables (P>0.05).
321
Part B (3-min cycling test)
323
The mean power output profile for all participants during the 3-min all-out cycling test is 324 shown in figure 2b for the PL and IBP conditions. During the PL trial, power output declined progressive decline in M-wave (P<0.01, figure 4b ) and EMG amplitudes (P<0.01, figure 4a ).
334
The profiles of the M-wave and EMG amplitudes were not altered following IBP ingestion at 
DISCUSSION
339
Contrary to our experimental hypotheses, the principal findings of this study were that acute 340 ingestion of 400 mg of IBP in a 'fresh' state had no effect on fatigue development or 65.4 ± 6.4 65.9 ± 5.9 Critical power, CP (W) 288 ± 31 292 ± 28 Wʹ (kJ) 13.6 ± 2.4 13.7 ± 2.8
Neuromuscular function
End-exercise M-wave amplitude (%) 84 ± 21 83 ± 18 End-exercise EMG amplitude (%) 54 ± 17 57 ± 14 MVC, maximal voluntary contraction; CT, critical torque measured in the last 6 contractions; CP, critical power measured in the last 30 s of the 3-minute maximal cycling test; pTw, potentiated twitch force; VA, voluntary activation measured using the interpolated twitch method technique; EMG, electromyography; N.m, newton metres; N.m.s-1, newton metres per second; ms, milliseconds. 
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